HOME >> MEDICINE >> NEWS
Experimental pill found to improve symptoms in patients with non-small-cell lung cancer

ORLANDO, FLA. (May 19, 2002, 12:00 p.m., EST) An experimental pill has been found to improve symptoms and quality of life in patients with non-small-cell lung cancer, according to research findings presented by Ronald B. Natale, M.D., Acting Medical Director at Cedars-Sinai Comprehensive Cancer Center, and lead author of the study. The pill, called ZD 1839 (Iressa) is one of a new class of drugs that targets and blocks a key growth signal in cancer cells.

The study, presented at the 38th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, evaluated 216 patients with recurrent non-small-cell lung cancer who had undergone two or more rounds of chemotherapy. One group of patients received 250 mg of ZD 1839 (Iressa) daily, while the second group received ZD 1839 at 500 mg each day until the disease progressed. The investigators found that lung cancer symptoms, such as cough, shortness of breath, chest pain or tightness, appetite and fatigue, were greatly improved in about 40 percent of patients. Further, they found that symptom improvement was associated with a longer survival.

Our results show that patients who felt better after taking ZD 1839, actually lived longer than those whose symptoms did not improve, said Dr. Natale. This is important because it shows that a daily pill reduced symptoms such to the extent that many of our patients were able to resume their normal activities and enjoy life for longer.

ZD 1839 (Iressa), a pill developed by AstraZeneca, has been found to work in both laboratory and clinical trials by targeting and blocking a key growth signaling mechanism in cancer cells called the epidermal growth factor receptor (EGFR). Otherwise known as HER1, the EGFR is a part of the HER kinase family of proteins that control cell growth and can stimulate the spread of cancer when over-expressed on malignant cells.

Non-small-cell lung cancer is the most common type of lung cancer,
'"/>

Contact: Kelli Stauning
kelli.stauning@cshs.org
310-423-3674
Cedars-Sinai Medical Center
19-May-2002


Page: 1 2 3

Related medicine news :

1. St. Jude scientist wins International Society of Experimental Hematology award
2. Experimental drug improves sleep in older patients, Wake Forest Baptist study shows
3. Experimental drug used to treat recurrent ovarian cancer shows promising results
4. Experimental treatment yields new hope for children battling cerebral palsy
5. Experimental drugs show promise in halting brain tumors
6. Experimental drugs reduce neuron death in rats following insulin shock
7. Experimental drug reverses effects of Fabry disease in mice
8. Experimental peptides prevent diabetes and halt its progression
9. Experimental testosterone patch shows promise for treating diminished sexual function in surgically menopausal women
10. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
11. Acupuncture found to lower elevations in blood pressure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... AR (PRWEB) , ... October 13, 2017 , ... ... with locations throughout Arkansas that offers insurance and financial preparation services, is providing ... the Rock City Rescue organization. , Rock City Rescue is a locally recognized ...
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology:
Cached News: